Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Excessive adipose tissue is potentially pathogenic due to its mass effects and through adverse metabolic/immune responses, which may lead to cardiovascular disease risk factors (eg, type 2 diabetes mellitus, hypertension, dyslipidemia, and possibly atherosclerosis itself). Positive caloric balance in genetically/environmentally susceptible patients may result in adipocyte hypertrophy, visceral adipose tissue accumulation, and ectopic fat deposition, all causally associated with metabolic disease, and all anatomic manifestations of "adiposopathy" (a term used to describe adipose tissue pathology). Weight loss through improved nutrition, increased physical activity, and weight loss agents (ie, orlistat and sibutramine) improves adiposopathy and improves many metabolic diseases whose prevalence are directly associated with an increase in body fat and sedentary lifestyle. Cannabinoid receptor antagonists improve adiposopathy through weight reduction and favorable metabolic effects upon multiple body organs (including adipocytes). Peroxisome proliferator-activated receptor-gamma agonists may improve adiposopathy through recruitment of functional fat cells and apoptosis of dysfunctional fat cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Potential adverse experiences include [[50], [59], [60], [61], [62]]:•Palpitation•Tachycardia•Increased blood pressure•Overstimulation•Tremor•Dizziness•Insomnia•Dysphoria•Headache•Dryness of mouth•Dysgeusia•Diarrhea•Constipation•Contraindicated in pregnancy”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [60]
In the citing paper
“May increase risk of cholelithiasis”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [60]
In the citing paper
“Orlistat inhibits absorption of a vitamin E acetate supplements by approximately 60%”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [60]
In the citing paper
“Cyclosporine plasma levels may be reduced when orlistat is co-administered with cyclosporine; cyclosporine should be taken at least 3 hours before or after orlistat in patients taking both drugs”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [60]
Citations
Cites
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Effect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
Systematic Review: An Evaluation of Major Commercial Weight Loss Programs in the United States
Tsai, A. G., & Wadden, T. A. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00012 · Cited by 815
Does central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753
Bassuk, S. S., & Manson, J. E. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00160.2005 · Cited by 744
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Self-citationBays, H. E., Chapman, R. H., Grandy, S., & the SHIELD Investigators’ Group (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01336.x · Cited by 510
Self-citationLarson-Meyer, D. E., Heilbronn, L. K., Redman, L. M., Newcomer, B. R., Frisard, M. I., Anton, S., Smith, S. R., Alfonso, A., Ravussin, E., & the Pennington CALERIE Team (2006) · Diabetes Care · doi:10.2337/dc05-2565 · Cited by 504
RAVUSSIN, E., & SMITH, S. R. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04292.x · Cited by 462
Research works printed but not linked: 4
- Bays H: Adiposopathy: defining, diagnosing, and establishing indications to treat “sick fat”: what are the regulatory considerations? US Endocrine Disease 2006, 2:12–14.
- Bays H: Adiposopathy: the endocannabinoid system as a therapeutic treatment target for dysfunctional “sick” fat. California J Health System Pharmacy 2007, 19:32–39.
- Genaer a Press Release: Genaera Corporation Announces Presentation of Data on Trodusquemine Mechanism of Action in Obesity. Available at http://www.genaera.com/press_room.php?page=134 . Accessed January 16, 2007.
- John-Soway J: Implications of Viewing Obesity as a Disease. Available at http://www.ama-assn.org/ama/pub/category/15630.html . Accessed February 28, 2007.
Cited by
Bays, H. E., González-Campoy, J. M., Bray, G. A., Kitabchi, A. E., Bergman, D. A., Schorr, A. B., Rodbard, H. W., & Henry, R. R. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.343 · Cited by 530
Self-citationBays, H. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.038 · Cited by 431
“Surgical removal of VAT through omentectomy plus adjustable gastric banding may improve glucose metabolism (oral glucose tolerance, insulin sensitivity, and fasting glucose and insulin levels) more than adjustable gastric banding (141).”
BackgroundInfluentialSelf-citation“Sick Fat,” Metabolic Disease, and Atherosclerosis
Bays, H. E. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.10.015 · Cited by 236
Self-citationLocal adipose tissue renin-angiotensin system
Cassis, L. A., Police, S. B., Yiannikouris, F., & Thatcher, S. E. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0019-9 · Cited by 223
“In the past, adipocytes were recognized as an inert energy source; however, adipocytes are now known to synthesize and secrete proinflammatory factors such as cytokines, acute-phase response proteins, chemotactic/chemoattractants, eicosanoids, prostaglandins, and potentially anti-inflammatory effectors (eg, adiponecti…”
BackgroundAnti-obesity drugs: a review about their effects and their safety
Derosa, G., & Maffioli, P. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.675326 · Cited by 185
“1 Phentermine Phentermine was first approved by the US FDA in 1959 [24], and due to its generic status, phentermine was the most commonly prescribed appetite suppressant [25].”
Background
Metadata
- Authors
- Bays, H., Rodbard, H. W., Schorr, A. B., & González-Campoy, J. M.
- Affiliations
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Corresponding author
- Bays, Harold
- Venue
- Current Treatment Options in Cardiovascular Medicine
- Published
- 2007-07-09
- Volume
- 9
- Issue
- 4
- Pages
- 259-271
- ISSN
- 1092-8464 (ISSN-L)
- 1534-3189
- OpenAlex
- W2075718586
- Cited by
- 36
- References
- 49
- Citations by year
- 2022: 1 · 2021: 2 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 1 · 2014: 5 · 2013: 1 · 2012: 6
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Treatment Options in Cardiovascular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- adiposopathy, adipose tissue, cardiovascular risk, type 2 diabetes, hypertension, dyslipidemia, atherosclerosis, visceral adipose tissue, ectopic fat deposition, adipocyte hypertrophy, energy balance, weight loss, orlistat, sibutramine, cannabinoid receptor antagonists, peroxisome proliferator-activated receptor gamma agonists, adipocyte apoptosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk. https://app.cochat.ai/papers/10.1007/s11936-007-0021-6
- The paper
- Bays, H., Rodbard, H. W., Schorr, A. B., & González-Campoy, J. M. (2007). Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk. Current Treatment Options in Cardiovascular Medicine. https://doi.org/10.1007/s11936-007-0021-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.